Published in Hepatology on June 01, 2010
Drug-induced autoimmune-like hepatitis. Dig Dis Sci (2011) 2.86
Bleeding complications and liver injuries during phenprocoumon treatment: a multicentre prospective observational study in internal medicine departments. Dtsch Arztebl Int (2013) 2.37
Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology (2011) 2.25
EU's new pharmacovigilance legislation: considerations for biosimilars. Drug Saf (2014) 2.12
Persistent Liver Biochemistry Abnormalities Are More Common in Older Patients and those With Cholestatic Drug Induced Liver Injury. Am J Gastroenterol (2015) 2.08
Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology (2013) 1.81
Serum proteomic profiling in patients with drug-induced liver injury. Aliment Pharmacol Ther (2012) 1.55
Drug-induced cholestasis. Hepatology (2011) 1.39
Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. Gastroenterology (2014) 1.31
Population-representative incidence of drug-induced acute liver failure based on an analysis of an integrated health care system. Gastroenterology (2015) 1.30
Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives. Gastroenterology (2013) 1.24
Drug-Induced Liver Injury: Twenty Five Cases of Acute Hepatitis Following Ingestion of Polygonum multiflorum Thunb. Gut Liver (2011) 1.19
Hepatic safety of antibiotics used in primary care. J Antimicrob Chemother (2011) 1.07
Drug-induced liver injury: present and future. Clin Mol Hepatol (2012) 1.06
Clinical and histopathologic features of fluoroquinolone-induced liver injury. Clin Gastroenterol Hepatol (2011) 1.05
Liver Injury from Herbal, Dietary, and Weight Loss Supplements: a Review. J Clin Transl Hepatol (2015) 1.03
Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database. Drug Saf (2015) 1.02
An Update on Drug-induced Liver Injury. J Clin Exp Hepatol (2012) 1.01
Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting. J Hepatol (2013) 1.01
Duloxetine hepatotoxicity: a case-series from the drug-induced liver injury network. Aliment Pharmacol Ther (2010) 0.96
Drug- and Herb-Induced Liver Injury in Clinical and Translational Hepatology: Causality Assessment Methods, Quo Vadis? J Clin Transl Hepatol (2013) 0.96
Detection of anti-isoniazid and anti-cytochrome P450 antibodies in patients with isoniazid-induced liver failure. Hepatology (2014) 0.93
Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review. Expert Rev Gastroenterol Hepatol (2015) 0.92
Evolution of the Food and Drug Administration approach to liver safety assessment for new drugs: current status and challenges. Drug Saf (2014) 0.89
Clinical and histologic features of azithromycin-induced liver injury. Clin Gastroenterol Hepatol (2014) 0.89
Comparative analysis of portal hepatic infiltrating leucocytes in acute drug-induced liver injury, idiopathic autoimmune and viral hepatitis. Clin Exp Immunol (2015) 0.88
Clinical and histological features of idiosyncratic acute liver injury caused by temozolomide. Dig Dis Sci (2012) 0.88
Herbal hepatotoxicity: challenges and pitfalls of causality assessment methods. World J Gastroenterol (2013) 0.87
Acute liver injury due to flavocoxid (Limbrel), a medical food for osteoarthritis: a case series. Ann Intern Med (2012) 0.87
Drug-induced liver injury caused by intravenously administered medications: the Drug-induced Liver Injury Network experience. J Clin Gastroenterol (2013) 0.85
A Text Searching Tool to Identify Patients with Idiosyncratic Drug-Induced Liver Injury. Dig Dis Sci (2015) 0.85
Features of Autoimmune Hepatitis in Patients With Drug-induced Liver Injury. Clin Gastroenterol Hepatol (2016) 0.84
Profiles of serum cytokines in acute drug-induced liver injury and their prognostic significance. PLoS One (2013) 0.84
Drug-Induced Liver Injury Network Causality Assessment: Criteria and Experience in the United States. Int J Mol Sci (2016) 0.81
Evaluation considerations for EHR-based phenotyping algorithms: A case study for drug-induced liver injury. AMIA Jt Summits Transl Sci Proc (2013) 0.81
Herbal medicine-related hepatotoxicity. World J Hepatol (2015) 0.80
Amoxicillin-Clavulanate-Induced Liver Injury. Dig Dis Sci (2016) 0.80
Identification and Characterization of Cefazolin-Induced Liver Injury. Clin Gastroenterol Hepatol (2014) 0.79
DILI: New Insights into Diagnosis and Management. Curr Hepat Rep (2013) 0.78
Causes, Features, and Outcomes of Drug-Induced Liver Injury in 69 Children from China. Gut Liver (2015) 0.78
Drug-induced steatohepatitis. Clin Liver Dis (2013) 0.78
Diagnosis: Liver biopsy differentiates DILI from autoimmune hepatitis. Nat Rev Gastroenterol Hepatol (2011) 0.76
Suspected Liver Injury and the Dilemma of Causality. Dig Dis Sci (2017) 0.76
Herbal and dietary supplement-induced liver injury. Gastroenterol Hepatol (N Y) (2011) 0.76
Minocycline hepatotoxicity: Clinical characterization and identification of HLA-B∗35:02 as a risk factor. J Hepatol (2017) 0.76
Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis. Biologics (2016) 0.75
Hepatotoxicity Associated with the Use of Anti-TNF-α Agents. Drug Saf (2016) 0.75
Severe Acute Hepatocellular Injury Attributed to OxyELITE Pro: A Case Series. Dig Dis Sci (2016) 0.75
Clinical Presentations and Outcomes of Bile Duct Loss caused by Drugs and Herbal and Dietary Supplements. Hepatology (2016) 0.75
Liver Function Test Abnormalities in Depressed Patients Treated with Antidepressants: A Real-World Systematic Observational Study in Psychiatric Settings. PLoS One (2016) 0.75
Drug-induced liver injury: Do we know everything? World J Hepatol (2017) 0.75
Risk of Liver Injury Associated with Green Tea Extract in SLIMQUICK(®) Weight Loss Products: Results from the DILIN Prospective Study. Drug Saf (2016) 0.75
Research Advances on Hepatotoxicity of Herbal Medicines in China. Biomed Res Int (2016) 0.75
Identification and Characterization of Fenofibrate-Induced Liver Injury. Dig Dis Sci (2017) 0.75
Death and Liver Transplantation within Two Years of Onset of Drug-Induced Liver Injury. Hepatology (2017) 0.75
Drug-induced liver injury: recent advances in diagnosis and risk assessment. Gut (2017) 0.75
Preliminary Results of a Novel Algorithmic Method Aiming to Support Initial Causality Assessment of Routine Pharmacovigilance Case Reports for Medication-Induced Liver Injury: The PV-RUCAM. Drug Saf (2017) 0.75
Development of a modified lymphocyte transformation test for diagnosing drug-induced liver injury associated with an adaptive immune response. J Immunotoxicol (2017) 0.75
A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther (1981) 69.83
Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol (1993) 7.63
Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol (1990) 5.66
Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology (2008) 5.45
Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology (1997) 3.68
Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology (2002) 3.64
Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology (2005) 3.52
Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf (2009) 3.48
Causality assessment of adverse reactions to drugs--II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol (1993) 2.89
Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology (2001) 2.40
Drug-induced liver injury: summary of a single topic clinical research conference. Hepatology (2006) 2.24
Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry. Hepatology (2006) 2.12
Clinical diagnostic scale: a useful tool in the evaluation of suspected hepatotoxic adverse drug reactions. J Hepatol (2000) 1.84
Drug-induced liver injury network (DILIN). Hepatology (2004) 1.64
Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury. Hepatology (2008) 1.53
Drug-induced liver injury: mechanisms and test systems. Hepatology (2001) 1.49
Drug-induced liver disease. Clin Liver Dis (2000) 1.46
Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic. Aliment Pharmacol Ther (2006) 1.43
The impact of eosinophilia and hepatic necrosis on prognosis in patients with drug-induced liver injury. Aliment Pharmacol Ther (2007) 1.41
Immune-mediated drug-induced liver disease. Clin Liver Dis (2002) 1.38
Agreement of expert judgment in causality assessment of adverse drug reactions. Eur J Clin Pharmacol (2005) 1.33
Evaluation of naranjo adverse drug reactions probability scale in causality assessment of drug-induced liver injury. Aliment Pharmacol Ther (2008) 1.29
Etiology of new-onset jaundice: how often is it caused by idiosyncratic drug-induced liver injury in the United States? Am J Gastroenterol (2007) 1.24
The burden of acute nonfulminant drug-induced hepatitis in a United States tertiary referral center [corrected]. J Clin Gastroenterol (2005) 1.18
Inter-expert agreement of seven criteria in causality assessment of adverse drug reactions. Br J Clin Pharmacol (2007) 1.10
Inpatient admissions for drug-induced liver injury: results from a single center. Dig Dis Sci (2008) 0.92
A new method for assessing drug causation provided agreement with experts' judgment. J Clin Epidemiol (2006) 0.91
Diagnosis, management, and treatment of hepatitis C: an update. Hepatology (2009) 22.53
A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology (2003) 16.40
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med (2010) 13.33
Diagnosis, management, and treatment of hepatitis C. Hepatology (2004) 11.62
A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab (2009) 11.46
Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med (2002) 11.38
Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology (2005) 10.66
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology (2011) 8.95
Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med (2006) 8.37
Liver biopsy. Hepatology (2009) 7.61
Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology (2008) 6.15
Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology (2008) 5.45
Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology (2005) 3.95
Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology (2009) 3.88
Measurement of serum acetaminophen-protein adducts in patients with acute liver failure. Gastroenterology (2006) 3.85
Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf (2009) 3.48
Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA (2011) 3.37
Natural history of hepatitis C. Clin Liver Dis (2005) 3.34
Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J Hepatol (2005) 3.18
The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol (2003) 3.04
Screening for Wilson disease in acute liver failure: a comparison of currently available diagnostic tests. Hepatology (2008) 3.04
Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology (2011) 2.97
NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology (2002) 2.96
Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol (2010) 2.96
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology (2009) 2.92
Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. Hepatology (2005) 2.91
Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology (2010) 2.86
Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology (2008) 2.66
Autoimmune acute liver failure: proposed clinical and histological criteria. Hepatology (2011) 2.64
Complications and use of intracranial pressure monitoring in patients with acute liver failure and severe encephalopathy. Liver Transpl (2005) 2.63
Endoscopic Transpapillary Gallbladder Stent Placement Is Safe and Effective in High-Risk Patients Without Cirrhosis. Dig Dis Sci (2014) 2.62
Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol (2007) 2.58
Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomarkers Prev (2012) 2.57
Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology (2011) 2.44
The prevalence and risk factors associated with esophageal varices in subjects with hepatitis C and advanced fibrosis. Gastrointest Endosc (2006) 2.43
Dance and reducing television viewing to prevent weight gain in African-American girls: the Stanford GEMS pilot study. Ethn Dis (2003) 2.41
Initial experience with EUS-guided Tru-cut biopsy of benign liver disease. Gastrointest Endosc (2009) 2.30
Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology (2010) 2.28
Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology (2011) 2.25
Drug-induced liver injury: summary of a single topic clinical research conference. Hepatology (2006) 2.24
Intensive care of patients with acute liver failure: recommendations of the U.S. Acute Liver Failure Study Group. Crit Care Med (2007) 2.17
Liver transplantation for hepatocellular carcinoma. Gastroenterology (2005) 2.15
An after-school obesity prevention program for African-American girls: the Minnesota GEMS pilot study. Ethn Dis (2003) 2.12
Declining liver utilization for transplantation in the United States and the impact of donation after cardiac death. Liver Transpl (2013) 2.07
Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology (2006) 2.06
Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatology (2003) 2.05
Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol (2005) 2.04
Liver transplant recipient survival benefit with living donation in the model for endstage liver disease allocation era. Hepatology (2011) 2.01
Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology (2011) 2.01
The Fun, Food, and Fitness Project (FFFP): the Baylor GEMS pilot study. Ethn Dis (2003) 2.00
Endoscopic therapy with 2-octyl-cyanoacrylate for the treatment of gastric varices. Dig Dis Sci (2014) 1.99
Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. Hepatology (2011) 1.98
Searching for a needle in a haystack: use of ICD-9-CM codes in drug-induced liver injury. Am J Gastroenterol (2007) 1.98
Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology (2005) 1.97
Vancomycin-resistant enterococcal colonization and infection in liver transplant candidates and recipients: a prospective surveillance study. Clin Infect Dis (2005) 1.93
Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease. Hepatology (2010) 1.91
Validity and reliability of activity measures in African-American girls for GEMS. Med Sci Sports Exerc (2003) 1.86
Fulminant hepatitis A virus infection in the United States: Incidence, prognosis, and outcomes. Hepatology (2006) 1.83
Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology (2014) 1.83
Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology (2013) 1.81
A framework for management of hepatitis C in prisons. Ann Intern Med (2006) 1.80
Fulminant hepatitis B due to a lamivudine-resistant mutant of HBV in a patient coinfected with HIV. Gastroenterology (2002) 1.79
An assessment of statin safety by hepatologists. Am J Cardiol (2006) 1.78
Nutritional model of steatohepatitis and metabolic syndrome in the Ossabaw miniature swine. Hepatology (2009) 1.78
Unexplained elevations in alanine aminotransferase in individuals with the metabolic syndrome: results from the third National Health and Nutrition Survey (NHANES III). Am J Med Sci (2005) 1.76
Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C. Gastroenterology (2006) 1.73
Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. AIDS (2005) 1.71
DNA polymorphisms and response to treatment in patients with chronic hepatitis C: results from the HALT-C trial. J Hepatol (2008) 1.71
Relationship between hepatitis C and microalbuminuria: results from the NHANES III. Kidney Int (2005) 1.71
Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease. Hepatology (2008) 1.70
Biliary tract complications after orthotopic liver transplantation with choledochocholedochostomy anastomosis: endoscopic findings and results of therapy. Gastrointest Endosc (2002) 1.70
Do type and duration of antiretroviral therapy attenuate liver fibrosis in HIV-hepatitis C virus-coinfected patients? Clin Infect Dis (2005) 1.66
Mechanisms of drug-induced liver injury: from bedside to bench. Nat Rev Gastroenterol Hepatol (2011) 1.65
Hepatitis C and renal disease: an update. Am J Kidney Dis (2003) 1.65
Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. J Hepatol (2010) 1.63
Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence. Liver Transpl (2007) 1.61
HFE C282Y mutations are associated with advanced hepatic fibrosis in Caucasians with nonalcoholic steatohepatitis. Hepatology (2007) 1.60
Impact of nighttime and weekend liver transplants on graft and patient outcomes. Liver Transpl (2012) 1.60
Child- and parent-targeted interventions: the Memphis GEMS pilot study. Ethn Dis (2003) 1.59
Laboratory test results after living liver donation in the adult-to-adult living donor liver transplantation cohort study. Liver Transpl (2011) 1.59
Variability in the upper limit of normal for serum alanine aminotransferase levels: a statewide study. Hepatology (2009) 1.59
Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation. Liver Transpl (2007) 1.58
Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology (2010) 1.58
Use of complementary and alternative medicine in patients with liver disease. Am J Gastroenterol (2002) 1.57
The Study of the Effects of Diet on Metabolism and Nutrition (STEDMAN) weight loss project: Rationale and design. Contemp Clin Trials (2005) 1.57
Treatment of chronic hepatitis C in HIV/HCV-coinfection with interferon alpha-2b+ full-course vs. 16-week delayed ribavirin. Hepatology (2004) 1.56
Lipid-lowering agents that cause drug-induced hepatotoxicity. Clin Liver Dis (2007) 1.56
Gastrointestinal histoplasmosis in the acquired immunodeficiency syndrome: report of 18 cases and literature review. Diagn Microbiol Infect Dis (2006) 1.55
Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients. Liver Transpl (2006) 1.55
Patient knowledge about disease self-management in cirrhosis. Am J Gastroenterol (2013) 1.55
Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury. Hepatology (2008) 1.53
Serum vitamin D concentrations and unexplained elevation in ALT among US adults. Dig Dis Sci (2011) 1.52
Renal outcomes after liver transplantation in the model for end-stage liver disease era. Liver Transpl (2009) 1.49